Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis

Molecular Therapy

Volumn 7, Issue 2, 2003, Pages 262-270

  Brewis, N D ^a   Phelan, A ^a   Normand, N ^a   Choolun, E ^b   O'Hare, P ^a  

^a MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Apoptosis; BH3; Entisense; Phosphorothioate; Photodynamic; VP22

Indexed keywords

CELL PROTEIN; LIPOSOME; MUTANT PROTEIN; OLIGONUCLEOTIDE; PEPTIDE; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL 2; VIRUS FUSION PROTEIN; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL SCREENING; CELL STRAIN COS1; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; GENE THERAPY; HERPES VIRUS; MICROSCOPY; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TRANSPORT; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ANIMALIA; HERPES; HERPESVIRIDAE; SIMPLEXVIRUS;

EID: 0037303782     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00054-0     Document Type: Article

References (16)

1. Gewirtz, A. M., Stein, C. A., and Glazer, P. M. (1996). Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93: 3161-3163.
2. Luft, F. C. (1998). Making sense out of antisense oligodeoxynucleotides delivery: Getting there is half the fun. J. Mol. Med. 76: 75-76.
3. Wadia, J. S., and Dowdy, S. F. (2002). Protein transduction technology. Curr. Opin. Biotechnol. 13: 52-56.
4. Normand, N., van Leeuwen, H., and O'Hare, P. (2001). Particle formation by the HSV protein VP22 enabling protein and nucleic acid delivery. J. Biol. Chem. 276: 15042-15050.
5. Reed, J. C. (2002). Apoptosis-based therapies. Nat. Rev. Drug Discovery 1: 111-121.
6. Huang, D. C., and Strasser, A. (2000). BH3-only proteins-Essential initiators of apoptotic cell death. Cell. 103: 839-842.
7. Sattler, M., et al. (1997). Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275: 983-986.
8. Chittenden, T., et al. (1995). A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 14: 5589-5596.
9. Cosulich, S. C., Worrall, V., Hedge, P. J., Green, S., and Clarke, P. R. (1997). Regulation of apoptosis by BH3 domains in a cell-free system. Curr. Biol. 7: 913-920.
10. Zha, J., Harada, H., Osipov, K., Jockel, J., Waksman, G., and Korsmeyer, S. J. (1997). BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J. Biol. Chem. 272: 24101-24104.
11. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (11999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899-911.
12. Polster, B. M., Kinally, K. W., and Fiskum, G. (2001). BH3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability. J. Biol. Chem. 276: 37887-37894.
13. Finnegan, N. M., Curtin, J. F., Prevost, G., Morgan, B., and Cotter, T. G. (2001). Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br. J. Cancer 85: 115-121.
14. Holinger, E. P., Chittenden, T., and Lutz, R. J. (1999). Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. 274: 13298-13304.
15. Vieira, H. L., et al. (2002). Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-X(L). Oncogene 21: 1963-1977.
16. Schimmer, A. D., et al. (2001). The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 8: 725-733.